Chai Discovery | $70,000,000 | (Aug 7, 2025)
CodeKarma | $2,500,000 | (Aug 7, 2025)
Elion | $9,300,000 | (Aug 7, 2025)
Certified by Founder
Lodge
Shinobi Therapeutics
start up
United States
- South San Francisco, CA
- 13/12/2023
- Series A
- $51,000,000
Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs.
- Industry Biotechnology Research
- Website https://www.shinobitx.com/
- LinkedIn https://www.linkedin.com/company/shinobitx/about/
Related People
Dan KempFounder
United States -
New York City Metropolitan Area
Accomplished BioPharma Executive with experience in drug discovery (Novartis), translational and clinical development (Merck), sell-side, buy-side and M&A transactional BD (Takeda), Executive oversight (GammaDelta Therapeutics, Adaptate Therapeutics) and Operational Leadership (Cell Therapies at Takeda).
August | $7,000,000 | (Aug 7, 2025)
Stavtar Solutions | $55,000,000 | (Aug 7, 2025)
Tavily | $25,000,000 | (Aug 7, 2025)
Clay | $100,000,000 | (Aug 7, 2025)
Positive Development | $51,500,000 | (Aug 7, 2025)
Kontext | $10,000,000 | (Aug 6, 2025)
Wattch | $6,000,000 | (Aug 6, 2025)
Vendict | $10,000,000 | (Aug 6, 2025)
NuCicer | $11,500,000 | (Aug 6, 2025)